$74.05
1.421.96%
Last update: Jun 8, 1:39 PM
Corcept Therapeutics Inc Stock Guidance
CORTNASDAQ
Corcept Therapeutics (CORT) last issued guidance on April 30, 2026 for fiscal year 2026. The company guided revenue in the range of $950.00M - $1.05B for the period.
Compared to prior guidance, Corcept Therapeutics raised its revenue forecast from a prior range of $900.00M - $1.00B.
Corcept Therapeutics has issued 19 guidance updates between August 3, 2022 and April 30, 2026. During this period, the company raised its outlook 12 times and lowered it 4 times, providing investors with insight into management's evolving expectations.
Latest Guidance Date
Apr 30, 2026
Guidance Period
Full Year 2026
Revenue Guidance Range
$950.00M - $1.05B
Corcept Therapeutics Guidance History
Review all historical guidance issued by Corcept Therapeutics, including EPS and revenue forecasts across quarterly and annual periods.
Loading calendar...
FAQ
What is the most recent guidance for Corcept Therapeutics (CORT)?
The most recent guidance for Corcept Therapeutics (CORT) was reported on April 30, 2026 for the fiscal year 2026. Corcept Therapeutics forecasted revenue between $950.00M and $1.05B for the period.
What revenue range did Corcept Therapeutics (CORT) guide for?
Corcept Therapeutics (CORT) guided revenue in the range of $950.00M to $1.05B for the fiscal year 2026.
Did Corcept Therapeutics (CORT) raise or lower guidance?
Corcept Therapeutics (CORT) raised its revenue guidance from a prior range of $900.00M - $1.00B to $950.00M - $1.05B for the fiscal year 2026.
When did Corcept Therapeutics (CORT) last issue guidance?
Corcept Therapeutics (CORT) last issued guidance on April 30, 2026 for the fiscal year 2026.
